PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS‐4059/ONO‐4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B‐CELL MALIGNANCIES
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_136
Abstract: treat (ITT) is 71% and 57%, respectively (Figure 1). Conclusion: Ibrutinib dosed at 840 mg daily in combination with R‐ICE is well tolerated and enables HPC collection. Encouragingly, 89% of patients achieved a response; including… read more here.
Keywords: combination; study tirabrutinib; results phase; preliminary results ... See more keywords
A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14561
Abstract: Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s… read more here.
Keywords: waldenstr macroglobulinemia; study tirabrutinib; response; study ... See more keywords